A Study to Determine the Safety, Tolerability, and Efficacy of SHR-1209 in Patients With Familial Hypercholesterolemia

Inclusion Criteria: * Males and females ≥ 18 years of age * Diagnosis of homozygous familial hypercholesterolemia * Stable lipid-lowering therapies for at least 28 days * LDL cholesterol ≥ 130 mg/dl (3.4 mmol/L) * Triglyceride ≤ 400 mg/dL (4.5 mmol/L) * Bodyweight of ≥ 40 kg at screening. Exclusion Criteria: * LDL or plasma apheresis within 8 weeks prior to randomization * New York Heart Association (NYHA) class III or IV or last known left ventricular ejection fraction \< 30% * Myocardial infarction, unstable angina, percutaneous coronary intervention, coronary artery bypass graft or stroke within 3 months of randomization, Planned cardiac surgery or revascularization, Uncontrolled cardiac arrhythmia * Liver transplant history. * Uncontrolled hypertension. * Moderate to severe renal dysfunction. * Active liver disease or hepatic dysfunction. * Known sensitivity to any of the products to be administered during dosing